BASF’s Legal Gambit Against Apple Overshadows a Steady Week of Operational Progress

The chemical giant’s decision to sue Apple in a Texas courtroom marks an unusual departure from its industrial roots, yet the shares have barely flinched. BASF filed its patent infringement complaint in Midland, Texas on Thursday, alleging that Apple’s facial authentication technology violates its intellectual property across dozens of iPhone and iPad models. For a company better known for polymers and crop protection than litigation, the move signals a willingness to monetize its patent portfolio against one of the world’s most valuable technology firms. The case, as Reuters reported, is expected to drag on for months with an inherently uncertain outcome.

Investors have taken the news in stride. The stock traded at €53.45, a hair above Wednesday’s close of €53.36, leaving the shares roughly three percent shy of their 52-week high of €55.05 set in April. That muted reaction makes sense: a courtroom victory could unlock licensing revenue, but a defeat would leave the core chemicals operations untouched. The real valuation driver, as ever, remains demand in the cyclical chemicals market.

Ludwigshafen’s Newly Modernized Line Tells a Different Story

While the legal team was busy in Texas, BASF’s operational side delivered a reminder of where the company’s industrial priorities lie. On Wednesday, the group formally brought its fully revamped acid chlorides and chloroformates plant at the Ludwigshafen Verbund site back online. These intermediates feed a cascade of downstream specialty chemicals produced at the sprawling complex, and the investment underscores management’s commitment to its largest manufacturing hub even as portfolio divestitures continue.

The plant news barely moved the needle pre-market, where shares indicated around €53.49, roughly 0.2 percent above the prior session’s close. With a market capitalization hovering near €46 billion, the market’s focus appears fixed elsewhere — namely on the cadence of capital returns and the direction of analyst sentiment.

Buybacks Continue in the Background

The share repurchase program, authorized just over a week ago, is proceeding according to plan. Between August 24 and August 28, BASF bought back 591,251 of its own shares, bringing the cumulative total since the program’s early-August launch to roughly 2.39 million securities. The steady execution signals that management intends to maintain shareholder distributions while simultaneously funding capital expenditure at Ludwigshafen — a balancing act that defines the current strategic phase.

Should investors sell immediately? Or is it worth buying BASF?

Analysts Split as the Rally Matures

The divergent views on BASF’s trajectory came into sharp relief on Thursday, when two research houses published opposing calls. Citigroup lifted its price target from €58 to €60 while reaffirming a “Buy” rating. MWB Research, by contrast, downgraded the stock from “Buy” to “Hold,” leaving its target unchanged at €55. The timing of these conflicting assessments coincides with the Ludwigshafen announcement, though the underlying reasoning appears rooted in differing interpretations of the recent share price run.

That run has been substantial: the stock has gained 20 percent since the start of the year. The advance explains why some analysts are growing cautious about near-term upside while others see room for further appreciation. Meanwhile, the broader German chemicals sector remains under pressure, and the VCI industry association has cautioned that the Middle East conflict could distort readings of underlying demand conditions — a reminder that geopolitical noise is complicating an already soft demand picture.

Pricing Power Meets a Soft Demand Environment

In North America, BASF has raised prices for caprolactam, polyamide 6, and polyamide 6/66 copolymers, according to secondary industry reports that could not be independently verified. Additional products are also said to carry higher price tags. These increases sit awkwardly against the weak demand backdrop flagged by MWB Research in its downgrade rationale, illustrating the tension between cost pass-through and volume softness that defines the current chemicals cycle.

What to Watch Next

The market’s attention now turns to the third-quarter reporting date of October 28, when BASF will provide its next formal update. Until then, the interplay between operational milestones, the ongoing buyback, and the slow-burning Apple litigation will shape the narrative. The patent case offers a potential upside kicker that most chemical investors never factored into their models, but the more prosaic question of end-market demand will ultimately determine whether the stock’s 2024 rally has further to run.